• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Erythropoiesis-Stimulating Agents and Mortality.

作者信息

Drüeke Tilman B, Massy Ziad A

机构信息

Inserm U-1018, Team 5, Centre de recherche en épidémiologie et santé des populations, Versailles Saint-Quentin-en-Yvelines University (Paris-Ile-de-France-Ouest University), Paris-Sud University, and Paris Saclay University, Villejuif, France; and

Inserm U-1018, Team 5, Centre de recherche en épidémiologie et santé des populations, Versailles Saint-Quentin-en-Yvelines University (Paris-Ile-de-France-Ouest University), Paris-Sud University, and Paris Saclay University, Villejuif, France; and.

出版信息

J Am Soc Nephrol. 2019 Jun;30(6):907-908. doi: 10.1681/ASN.2019030266. Epub 2019 Apr 23.

DOI:10.1681/ASN.2019030266
PMID:31015256
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6551780/
Abstract
摘要

相似文献

1
Erythropoiesis-Stimulating Agents and Mortality.促红细胞生成素与死亡率
J Am Soc Nephrol. 2019 Jun;30(6):907-908. doi: 10.1681/ASN.2019030266. Epub 2019 Apr 23.
2
Analysis of Other Confounding Factors Is Mandatory before Considering That Long-Acting Erythropoiesis Stimulating Agents Are Deleterious to Patients on Dialysis.在考虑长效红细胞生成刺激剂对透析患者有害之前，必须分析其他混杂因素。
J Am Soc Nephrol. 2019 Sep;30(9):1771. doi: 10.1681/ASN.2019050505. Epub 2019 Aug 16.
3
Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis.慢性肾脏病患者中，达比加群酯与依泊汀α的死亡风险比较：系统评价与荟萃分析
Am J Kidney Dis. 2015 Jul;66(1):69-74. doi: 10.1053/j.ajkd.2014.12.012. Epub 2015 Jan 28.
4
Erythropoietin, the biology of erythropoiesis and epoetin alfa. An overview.促红细胞生成素、红细胞生成生物学及重组人促红细胞生成素α。综述。
J Reprod Med. 2001 May;46(5 Suppl):521-30.
5
Erythropoietin stimulating agents and epoetin alfa revisited: what's really relevant?促红细胞生成素刺激剂与阿法依泊汀再探讨：真正相关的是什么？
Clin J Am Soc Nephrol. 2008 Jul;3(4):935-7. doi: 10.2215/CJN.02300508. Epub 2008 Jun 25.
6
[Current issues in erythropoietin therapy of renal anemia].[肾性贫血促红细胞生成素治疗中的当前问题]
Lege Artis Med. 2007 Oct;17(10):667-73.
7
Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anemia: a systematic review.促红细胞生成素刺激剂治疗化疗所致贫血患者的剂量效率：一项系统评价
Clin Ther. 2014 Apr 1;36(4):594-610. doi: 10.1016/j.clinthera.2014.02.007. Epub 2014 Mar 18.
8
Sufficient liver erythropoietin synthesis is induced in hemodialysis patients not requiring erythropoiesis-stimulating agents.在不需要促红细胞生成剂的血液透析患者中，可诱导足够的肝脏促红细胞生成素合成。
Clin Nephrol. 2022 Sep;98(3):167-170. doi: 10.5414/CN110749.
9
Anemia Treatment by Erythropoiesis-stimulating Agents during the 6 Months before the Initiation of Hemodialysis: Comparison of Darbepoetin Alfa and Continuous Erythropoietin Receptor Activator.血液透析开始前6个月使用促红细胞生成剂治疗贫血：达贝泊汀α与持续促红细胞生成素受体激活剂的比较
Keio J Med. 2017 Sep 26;66(3):44-50. doi: 10.2302/kjm.2016-0009-OA. Epub 2016 Dec 19.
10
Epoetin alfa resistance in hemodialysis patients with chronic kidney disease: a longitudinal study.慢性肾脏病血液透析患者对促红细胞生成素α的抵抗：一项纵向研究。
Braz J Med Biol Res. 2018;51(7):e7288. doi: 10.1590/1414-431x20187288. Epub 2018 May 7.

引用本文的文献

1
Precision Medicine in Erythropoietin Deficiency and Treatment Resistance: A Novel Approach to Management of Anaemia in Chronic Kidney Disease.促红细胞生成素缺乏和治疗抵抗中的精准医学：慢性肾脏病贫血管理的新方法
Curr Issues Mol Biol. 2023 Aug 7;45(8):6550-6563. doi: 10.3390/cimb45080413.
2
Darbepoetin alfa injection versus epoetin alfa injection for treating anemia of Chinese hemodialysis patients with chronic kidney failure: A randomized, open-label, parallel-group, non-inferiority Phase III trail.聚乙二醇化促红细胞生成素α注射液与促红细胞生成素α注射液治疗中国慢性肾衰竭血液透析患者贫血的比较：一项随机、开放标签、平行组、非劣效性III期试验。
Chronic Dis Transl Med. 2022 Mar 29;8(1):59-70. doi: 10.1002/cdt3.13. eCollection 2022 Mar.
3
Investigation of the Relationship between Lean Muscle Mass and Erythropoietin Resistance in Maintenance Haemodialysis Patients: A Cross-Sectional Study.维持性血液透析患者瘦体重与红细胞生成素抵抗关系的调查：一项横断面研究。
Int J Environ Res Public Health. 2022 May 7;19(9):5704. doi: 10.3390/ijerph19095704.
4
Dynamics of Erythroferrone Response to Erythropoietin in Rats.大鼠中促红细胞生成素对促红细胞生成素铁蛋白的反应动力学
Front Pharmacol. 2022 Apr 20;13:876573. doi: 10.3389/fphar.2022.876573. eCollection 2022.
5
Optimizing detection of erythropoietin receptor agonists from dried blood spots for anti-doping application.优化从干血斑中检测促红细胞生成素受体激动剂用于反兴奋剂应用。
Drug Test Anal. 2022 Aug;14(8):1377-1386. doi: 10.1002/dta.3260. Epub 2022 Mar 30.
6
Long- Versus Short-Acting Erythropoiesis-Stimulating Agent Type and Mortality.长效与短效促红细胞生成素刺激剂类型与死亡率
Kidney Int Rep. 2020 Oct 10;6(1):214-218. doi: 10.1016/j.ekir.2020.10.003. eCollection 2021 Jan.
7
Erythropoietin Resistance in Patients with Chronic Kidney Disease: Current Perspectives.慢性肾脏病患者的促红细胞生成素抵抗：当前观点
Int J Nephrol Renovasc Dis. 2020 Oct 8;13:231-237. doi: 10.2147/IJNRD.S239151. eCollection 2020.

本文引用的文献

1
Types of Erythropoietin-Stimulating Agents and Mortality among Patients Undergoing Hemodialysis.接受血液透析患者的红细胞生成素刺激剂类型与死亡率。
J Am Soc Nephrol. 2019 Jun;30(6):1037-1048. doi: 10.1681/ASN.2018101007. Epub 2019 Apr 23.
2
Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).在开始透析前使用达贝泊汀治疗贫血和临床结局：来自用阿法依泊汀治疗降低心血管事件试验（TREAT）的分析。
Am J Kidney Dis. 2019 Mar;73(3):309-315. doi: 10.1053/j.ajkd.2018.10.006. Epub 2018 Dec 19.
3
Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease.用于治疗慢性肾脏病贫血的持续促红细胞生成素受体激活剂（CERA）
Cochrane Database Syst Rev. 2017 Aug 7;8(8):CD009904. doi: 10.1002/14651858.CD009904.pub2.
4
Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study.达比加群酯与促红细胞生成素α在开始血液透析的终末期肾病患者中的长期疗效比较：一项准实验队列研究。
Am J Kidney Dis. 2015 Jul;66(1):106-13. doi: 10.1053/j.ajkd.2015.02.339. Epub 2015 May 2.
5
Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis.慢性肾脏病患者中，达比加群酯与依泊汀α的死亡风险比较：系统评价与荟萃分析
Am J Kidney Dis. 2015 Jul;66(1):69-74. doi: 10.1053/j.ajkd.2014.12.012. Epub 2015 Jan 28.
6
Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis.促红细胞生成素用于治疗成人慢性肾脏病贫血：一项网状Meta分析
Cochrane Database Syst Rev. 2014 Dec 8;2014(12):CD010590. doi: 10.1002/14651858.CD010590.pub2.
7
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.阿法达贝泊汀治疗2型糖尿病和慢性肾病的一项试验。
N Engl J Med. 2009 Nov 19;361(21):2019-32. doi: 10.1056/NEJMoa0907845. Epub 2009 Oct 30.
8
Correction of anemia with epoetin alfa in chronic kidney disease.慢性肾脏病中使用促红细胞生成素α纠正贫血
N Engl J Med. 2006 Nov 16;355(20):2085-98. doi: 10.1056/NEJMoa065485.
9
Normalization of hemoglobin level in patients with chronic kidney disease and anemia.慢性肾脏病合并贫血患者血红蛋白水平的正常化。
N Engl J Med. 2006 Nov 16;355(20):2071-84. doi: 10.1056/NEJMoa062276.
10
The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.接受血液透析和促红细胞生成素治疗的心脏病患者中，正常血细胞比容值与低血细胞比容值的影响比较
N Engl J Med. 1998 Aug 27;339(9):584-90. doi: 10.1056/NEJM199808273390903.